In a new study, Novo Nordisk, the pharmaceutical firm behind Ozempic and Wegovy, boasts that one of its drugs can help lower the body mass index (BMI) of children between the ages of 6 and 12.
While the medicine was well tolerated, there are concerns about this category of medicines and possible pancreas problems, thyroid cancer risk and bone health over the lifetime.
Because these drugs are known to reduce or suppress appetite, giving them to kids could also put them at developmental risk.
Collection
[
|
...
]